Avalo Therapeutics, Inc.
AVTX-009
Hidradenitis Suppurativa (HS)
Resolved
7days ago
Phase 2 readout · Jun 30, 2026
What's at stake
Phase 2 trial results for AVTX-009 in Hidradenitis Suppurativa (HS) are due Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Phase 2 LOTUS trial in HS enrollment complete with topline data expected Q2 2026”